Biotech firms have trouble getting reliable access to capital throughout the long, unpredictable development, testing, and approval process. While it’s in some ways a typical high risk, potentially high reward business, biotech can provide life-saving innovations when the success finally materializes.
J.W. Verret, GMU law school professor and member of the SEC’s investor advisory committee, has ideas to help biotech and other small-cap companies access the public and exempt markets more efficiently. Verret talks about why current securities regulations, like Reg A and Reg FD, hamper small-cap companies and hobble their search for liquidity. He discusses small changes, and better outreach from the SEC to small-cap firms, that could tip the scales and help match money with innovations that could improve lives.
Podden och tillhörande omslagsbild på den här sidan tillhör Bloomberg Law. Innehållet i podden är skapat av Bloomberg Law och inte av, eller tillsammans med, Poddtoppen.
